American Society of Hirudotherapy

Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor

Comparative study published in The EMBO journal (2000)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyDrug DevelopmentRichardson JL et al. · The EMBO journal, 2000

Abstract

The serine proteinase alpha-thrombin plays a pivotal role in the regulation of blood fluidity, and therefore constitutes a primary target in the treatment of various haemostatic disorders. Haemadin is a slow tight- binding thrombin inhibitor from the land-living leech Haemadipsa sylvestris. Here we present the 3.1 A crystal structure of the human alpha-thrombin- haemadin complex. The N-terminal segment of haemadin binds to the active site of thrombin, forming a parallel beta-strand with residues Ser214-Gly216 of the proteinase. This mode of binding is similar to that observed in another leech-derived inhibitor, hirudin. In contrast to hirudin, however, the markedly acidic C-terminal peptide of haemadin does not bind the fibrinogen-recognition exosite, but interacts with the heparin-binding exosite of thrombin. Thus, haemadin binds to thrombin according to a novel mechanism, despite an overall structural similarity with hirudin. Haemadin inhibits both free and thrombomodulin-bound alpha-thrombin, but not intermediate activation forms such as meizothrombin. This specific anticoagulant ability of haemadin makes it an ideal candidate for an antithrombotic agent, as well as a starting point for the design of novel antithrombotics.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsBinding SitesCrystallography, X-RayHirudinsHumansIn Vitro TechniquesInvertebrate HormonesLeechesMacromolecular SubstancesModels, MolecularMolecular Sequence Data

Summary

The serine proteinase alpha-thrombin plays a pivotal role in the regulation of blood fluidity, and therefore constitutes a primary target in the treatment of various haemostatic disorders.

Why This Matters for Hirudotherapy

Using X-ray crystallography, this study resolved the 3.1 Angstrom structure of human alpha-thrombin bound to haemadin, a tight-binding thrombin inhibitor from the land leech Haemadipsa sylvestris, showing that its N-terminus blocks thrombin's active site like hirudin but its acidic C-terminus uniquely engages the heparin-binding exosite (exosite II) rather than the fibrinogen-recognition exosite that hirudin uses. It reports that haemadin inhibits both free and thrombomodulin-bound thrombin but not meizothrombin, which the authors note makes it a candidate antithrombotic and a template for designing new agents. This matters to the leech-secretome drug-discovery narrative because it documents a second leech anticoagulant with a distinct, well-defined molecular mechanism, illustrating the pharmacological diversity of leech-derived thrombin inhibitors. As a structural and biochemical study, it characterizes a single molecule's binding mode and does not by itself establish clinical efficacy or safety in patients.

Citation

Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor

Richardson JL et al. · The EMBO journal, 2000

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.